- Home
- FIVN vs APLS Comparison
FIVN vs APLS Comparison
Compare FIVN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVN
- APLS
- Stock Information
- Founded
- FIVN 2001
- APLS 2009
- Country
- FIVN United States
- APLS United States
- Employees
- FIVN N/A
- APLS N/A
- Industry
- FIVN EDP Services
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- FIVN Technology
- APLS Health Care
- Exchange
- FIVN Nasdaq
- APLS Nasdaq
- Market Cap
- FIVN 2.0B
- APLS 2.2B
- IPO Year
- FIVN 2014
- APLS 2017
- Fundamental
- Price
- FIVN $27.71
- APLS $18.25
- Analyst Decision
- FIVN Buy
- APLS Buy
- Analyst Count
- FIVN 21
- APLS 19
- Target Price
- FIVN $43.95
- APLS $37.39
- AVG Volume (30 Days)
- FIVN 2.2M
- APLS 1.9M
- Earning Date
- FIVN 08-07-2025
- APLS 07-31-2025
- Dividend Yield
- FIVN N/A
- APLS N/A
- EPS Growth
- FIVN N/A
- APLS N/A
- EPS
- FIVN N/A
- APLS N/A
- Revenue
- FIVN $1,074,633,000.00
- APLS $775,839,000.00
- Revenue This Year
- FIVN $11.81
- APLS $1.01
- Revenue Next Year
- FIVN $9.79
- APLS $22.14
- P/E Ratio
- FIVN N/A
- APLS N/A
- Revenue Growth
- FIVN 14.44
- APLS 48.04
- 52 Week Low
- FIVN $21.04
- APLS $16.10
- 52 Week High
- FIVN $49.90
- APLS $42.47
- Technical
- Relative Strength Index (RSI)
- FIVN 54.70
- APLS 48.67
- Support Level
- FIVN $26.06
- APLS $17.15
- Resistance Level
- FIVN $27.47
- APLS $18.60
- Average True Range (ATR)
- FIVN 0.96
- APLS 0.70
- MACD
- FIVN -0.05
- APLS -0.04
- Stochastic Oscillator
- FIVN 84.95
- APLS 45.25
About FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.